Adicet Bio, Inc.
Adicet Bio, Inc. (0HX7.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Adicet Bio, Inc. (0HX7.L), featuring income statements, balance sheets, and cash flow data.
Adicet Bio, Inc. (0HX7.L) Income Statement & Financial Overview
View the income breakdown for Adicet Bio, Inc. 0HX7.L across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $1.60M |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$1.60M |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $22.81M | $23.27M | $26.25M | $25.90M |
| SG&A Expenses | $7.07M | $7.47M | $6.90M | $6.95M |
| Operating Expenses | $29.89M | $30.74M | $33.15M | $32.85M |
| Total Costs & Expenses | $0.00 | $35.65M | $33.15M | $32.85M |
| Interest Income | $1.68M | $2.07M | $2.73M | $3.00M |
| Interest Expense | $0.00 | $1000.00 | $1000.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $1.62M | $1.59M | $1.60M |
| EBITDA | -$29.89M | -$27.10M | -$28.89M | -$28.30M |
| EBITDA Ratio | ||||
| Operating Income | -$29.89M | -$30.74M | -$33.15M | -$32.85M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $1.67M | $2.02M | $2.67M | $2.95M |
| Income Before Tax | -$28.21M | -$28.73M | -$30.48M | -$29.90M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$1.60M |
| Net Income | -$28.21M | -$28.73M | -$30.48M | -$29.90M |
| Net Income Ratio | ||||
| EPS | -$0.31 | -$0.32 | -$0.34 | -$0.33 |
| Diluted EPS | -$0.31 | -$0.32 | -$0.34 | -$0.33 |
| Weighted Avg Shares Outstanding | $91.07M | $87.87M | $90.85M | $90.63M |
| Weighted Avg Shares Outstanding (Diluted) | $91.07M | $87.87M | $90.85M | $90.63M |
Over the last four quarters, Adicet Bio, Inc. achieved steady financial progress, growing revenue from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit stayed firm with margins at N/A in Q1 2025 versus N/A in Q2 2024. Operating income totaled -$29.89M in Q1 2025, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$29.89M. Net income rose to -$28.21M, with EPS at -$0.31. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan